Cost-Effectiveness of Dulaglutide Versus Liraglutide for Management of Type 2 Diabetes Mellitus in Iran.

Ekhlasi M, Taheri S, Yousefi N

Value in health regional issues8 Sept 2022Cited by 3 (Europe PMC)

PMID36087364DOI10.1016/j.vhri.2022.07.005PepBankPUB-36087364

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In an Iranian diabetes model, projected treatment costs were 17 577.09 US dollars per patient for dulaglutide versus 18 517.54 for liraglutide.
In plain wordsIn computer projections, dulaglutide cost less than liraglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseTreatment costs
Study
n: not reported in source
5-state Markov model
Comparator
Liraglutide
Outcome group
Healthcare costs and utilization · Whole body
Source sentences
Summary
The average costs of treatment of patients with type 2 DM using the dulaglutide and liraglutide treatment regimens are 17 577.09 and 18 517.54 US dollars per patient, respectively, over a 10-year time horizon.
2 context sentences(design, population, supporting numbers)
Summary · context
This study intended to investigate the cost-effectiveness of dulaglutide compared with liraglutide in the management of patients with type 2 DM in Iran.
Summary · context
We conducted a cost-utility analysis using a 5-state Markov model from the health system perspective, over a 10-year time horizon, in 2018 in Iran.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3608736401
02Computer modelNot a test of Liraglutide aloneIn silicoOther
In an Iranian diabetes model, projected treatment costs were 18 517.54 US dollars per patient for liraglutide versus 17 577.09 for dulaglutide.
In plain wordsIn computer projections, liraglutide cost more than dulaglutide.
Peptide
Liraglutide
Outcome
IncreaseTreatment costs
Study
n: not reported in source
5-state Markov model
Comparator
Dulaglutide
Outcome group
Healthcare costs and utilization · Whole body
Source sentences
Summary
The average costs of treatment of patients with type 2 DM using the dulaglutide and liraglutide treatment regimens are 17 577.09 and 18 517.54 US dollars per patient, respectively, over a 10-year time horizon.
2 context sentences(design, population, supporting numbers)
Summary · context
This study intended to investigate the cost-effectiveness of dulaglutide compared with liraglutide in the management of patients with type 2 DM in Iran.
Summary · context
We conducted a cost-utility analysis using a 5-state Markov model from the health system perspective, over a 10-year time horizon, in 2018 in Iran.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3608736402
03Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In an Iranian diabetes model, dulaglutide had higher projected discounted quality-adjusted life-years than liraglutide.
In plain wordsIn computer projections, dulaglutide produced more quality-adjusted life-years than liraglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseDiscounted quality-adjusted life-years
Study
n: not reported in source
5-state Markov model
Comparator
Liraglutide
Outcome group
Healthcare costs and utilization · Whole body
Measurements
Discounted quality-adjusted life-years
5.56 QALYs
dulaglutide
Discounted quality-adjusted life-years
5.403 QALYs
liraglutide
Source sentences
Summary
In terms of effectiveness, the average discounted quality-adjusted life-year rates are estimated at 5.560 and 5.403 for the dulaglutide and liraglutide treatment regimens, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This study intended to investigate the cost-effectiveness of dulaglutide compared with liraglutide in the management of patients with type 2 DM in Iran.
Summary · context
We conducted a cost-utility analysis using a 5-state Markov model from the health system perspective, over a 10-year time horizon, in 2018 in Iran.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3608736403
04Computer modelNot a test of Liraglutide aloneIn silicoOther
In an Iranian diabetes model, liraglutide had lower projected discounted quality-adjusted life-years than dulaglutide.
In plain wordsIn computer projections, liraglutide produced fewer quality-adjusted life-years than dulaglutide.
Peptide
Liraglutide
Outcome
DecreaseDiscounted quality-adjusted life-years
Study
n: not reported in source
5-state Markov model
Comparator
Dulaglutide
Outcome group
Healthcare costs and utilization · Whole body
Measurements
Discounted quality-adjusted life-years
5.403 QALYs
liraglutide
Discounted quality-adjusted life-years
5.56 QALYs
dulaglutide
Source sentences
Summary
In terms of effectiveness, the average discounted quality-adjusted life-year rates are estimated at 5.560 and 5.403 for the dulaglutide and liraglutide treatment regimens, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This study intended to investigate the cost-effectiveness of dulaglutide compared with liraglutide in the management of patients with type 2 DM in Iran.
Summary · context
We conducted a cost-utility analysis using a 5-state Markov model from the health system perspective, over a 10-year time horizon, in 2018 in Iran.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3608736404
05Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
The Iranian diabetes model was sensitive to dulaglutide price and utility from its lower injection frequency.
In plain wordsIn computer analyses, dulaglutide price and benefits assigned to fewer injections influenced model results.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableModel sensitivity
Study
n: not reported in source
5-state Markov model
Outcome group
Healthcare costs and utilization · Whole body
Source sentences
Summary
The model is mostly sensitive to the price of dulaglutide and liraglutide, the hemoglobin A1c reduction of liraglutide, and the utility resulting from less injection frequency of dulaglutide, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This study intended to investigate the cost-effectiveness of dulaglutide compared with liraglutide in the management of patients with type 2 DM in Iran.
Summary · context
We conducted a cost-utility analysis using a 5-state Markov model from the health system perspective, over a 10-year time horizon, in 2018 in Iran.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3608736405
06Computer modelNot a test of Liraglutide aloneIn silicoOther
The Iranian diabetes model was sensitive to liraglutide price and HbA1c reduction.
In plain wordsIn computer analyses, liraglutide price and blood sugar reduction influenced model results.
Peptide
Liraglutide
Outcome
Not applicableModel sensitivity
Study
n: not reported in source
5-state Markov model
Outcome group
Healthcare costs and utilization · Whole body
Source sentences
Summary
The model is mostly sensitive to the price of dulaglutide and liraglutide, the hemoglobin A1c reduction of liraglutide, and the utility resulting from less injection frequency of dulaglutide, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This study intended to investigate the cost-effectiveness of dulaglutide compared with liraglutide in the management of patients with type 2 DM in Iran.
Summary · context
We conducted a cost-utility analysis using a 5-state Markov model from the health system perspective, over a 10-year time horizon, in 2018 in Iran.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3608736406

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.